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Abstract
Background: The normal growth and function of mammary epithelial cells depend on interactions
with the supportive stroma. Alterations in this communication can lead to the progression or
expansion of malignant growth. The human mammary gland contains two distinctive types of
fibroblasts within the stroma. The epithelial cells are surrounded by loosely connected intralobular
fibroblasts, which are subsequently surrounded by the more compacted interlobular fibroblasts.
The different proximity of these fibroblasts to the epithelial cells suggests distinctive functions for
these two subtypes. In this report, we compared the gene expression profiles between the two
stromal subtypes.
Methods: Fresh normal breast tissue was collected from reduction mammoplasty patients and
immediately placed into embedding medium and frozen on dry ice. Tissue sections were subjected
to laser capture microscopy to isolate the interlobular from the intralobular fibroblasts. RNA was
prepared and subjected to microarray analysis using the Affymetrix Human Genome U133
GeneChip®. Data was analyzed using the Affy and Limma packages available from Bioconductor.
Findings from the microarray analysis were validated by RT-PCR and immunohistochemistry.
Results: No statistically significant difference was detected between the gene expression profiles
of the interlobular and intralobular fibroblasts by microarray analysis and RT-PCR. However, for
some of the genes tested, the protein expression patterns between the two subtypes of fibroblasts
were significantly different.
Conclusion: This study is the first to report the gene expression profiles of the two distinct
fibroblast populations within the human mammary gland. While there was no significant difference
in the gene expression profiles between the groups, there was an obvious difference in the
expression pattern of several proteins tested. This report also highlights the importance of studying
gene regulation at both the transcriptional and post-translational level.
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Background
Breast cancer is the most commonly diagnosed cancer,
and is the second leading cause of cancer mortality in
women in the U.S. [1]. Metastasis of the tumor is the pri-
mary cause of morbidity and mortality. In late-stage breast
cancer, tumor metastasis can be found in several tissues,
including bone, lung, lymph node, and liver [2]. Because
metastasis is a major challenge in cancer management, a
better understanding of the metastatic progression is
required. Tumor progression and metastasis are both reg-
ulated by the surrounding microenvironment, i.e. the
local stroma. Therefore, studies targeted towards under-
standing the function of normal breast stroma will facili-
tate the development of methods for preventing breast
cancer metastasis.
Normal growth, function, and homeostasis of breast epi-
thelial cells depend on intricate interactions between the
numerous stromal cells within the mammary gland. The
stromal cells are composed of a diverse assortment of cell
types including the vasculature, adipocytes, resident
immune cells, and fibroblasts. These cells secrete multiple
cellular products, such as growth factors and extracellular
matrix components, which have profound effects the
behavior of the breast epithelial cells. Alterations in the
regular communications between these cells can lead to
the progression or expansion of malignant growth.
It is now well documented that stromal cells have a strik-
ing effect on the behavior of mammary epithelial cells in
culture [3-7] as well as on the formation, growth, and
metastasis of epithelial-derived tumors in vivo [8-11].
Both in vitro and in vivo studies have shown that epithelial
cell contact with tumor-derived or normal fibroblasts can
either promote or inhibit tumorigenic cell growth, respec-
tively [11,12]. In agreement with these reports, one study
using microarray analyses demonstrated that the gene
expression profiles of cancer-derived fibroblasts had a dis-
tinctive gene expression pattern that differentiated them
from normal breast stroma [13]. Furthermore, breast can-
cer stroma differs morphologically from the stroma found
in normal breast tissue. For example, in ductal carcinomas
in situ (DCIS), and most invasive breast carcinomas, the
stroma exhibits enhanced accumulation of fibroblasts
and a modified collagenized extracellular matrix com-
pared to its normal counterpart [3,14-19]. Understanding
the mechanisms of the interactions between cancerous or
normal epithelial cells and the stroma might lead to novel
methods for cancer therapies that target the function of
the resident stromal cells.
Most models of breast cancer development are studied
using mouse in vivo models. However, the stroma within
the human mammary gland is fundamentally different
from that in the mouse [20]. These differences make it dif-
ficult to ascertain the tumor/stromal interactions that
would occur in the human breast when epithelial cells are
implanted into the mouse mammary fat pad. Compared
to the human breast, the mouse mammary gland contains
large depots of adipose laced with small amounts of inter-
spersed connective tissue. The functional lobular units of
the mouse gland are embedded within the fat pad, and
have a considerable amount of space between the mini-
mally branched ducts. In contrast, the functional lobular
units of the human mammary gland are surrounded by
loose intralobular connective tissue, consisting primarily
of fibroblasts. This intralobular stroma is subsequently
surrounded by a more compact interlobular stroma,
which detaches the lobules and intralobular stroma from
any substantial direct contact with the adipose tissue [21].
Stemming from the observations that these stroma sub-
types differ in their physical location in relation to the
functional epithelial lobules, and that epithelial/stromal
interactions can promote or inhibit tumorigenesis, we
investigated the differences between the two distinct stro-
mas.
Methods
Sample Collection
This study was performed in accordance with the guide-
lines of the National Cancer Institute Review Board, pro-
tocol 02-C-0144. All patients provided written informed
consent. Fresh human mammary tissue was collected
from four (two Caucasian, one African-American, and one
Hispanic) female, pre-menopausal, reduction mammo-
plasty patients, ages ranging from 18 to 40 years old. The
tissue was embedded in Tissue-Tek O.C.T. embedding
medium (Sankura Finetek Inc., Torrance CA) and frozen
on dry ice immediately after surgery. Eight – 10 micron
sections of tissue were cut using a Leica 2800 Frigocut-E
cryostat (Bannockburn, IL). Every tenth section was sub-
jected to hematoxylin and eosin staining. For each patient
sample, sections with distinctive intralobular and inter-
lobular regions were selected for laser capture and micro-
array analysis.
Laser capture microdissection and microarrays
Laser capture microdissection (LCM) and microarrays
were performed by Cogenics, Inc. (Morrisville, NC).
Briefly, selected intralobular and interlobular stroma sec-
tions of frozen tissue were subjected to an AutoPix™ auto-
mated LCM system from Arcturus, using static image
settings. RNA was isolated from each specimen, pooled,
and then evaluated by spectrophotometry and by using an
Agilent Bioanalyzer before proceeding to sample amplifi-
cation. For each sample, 50 ng of total RNA was amplified
using Affymetrix Two-Cycle Target Labeling kit (Santa
Clara, CA). Ten micrograms of biotinylated cRNA spiked
with bioB, bioC, bioD, and cre as a control was hybridized
to the Affymetrix Human Genome U133 GeneChip® forBMC Cell Biology 2008, 9:46 http://www.biomedcentral.com/1471-2121/9/46
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16 h at 45°C. Following hybridization, arrays were
washed and stained with Affymetrix GeneChip Fluidics
Station. Stained arrays were scanned with an Affymetrix
GeneChip Scanner 3000. Quality check and preliminary
data analysis were carried out using Affymetrix GeneChip
Operating Software and Quality Reporter.
Microarray analysis
Microarray data were analyzed using the Affy package
available at the Bioconductor website http://www.biocon
ductor.org. The raw data were first background-corrected
by the Robust Multichip Average (RMA) method [22] and
then normalized by an invariant set method. Unsuper-
vised hierarchical clustering analysis was performed on
1,115 most variable genes. The difference of gene expres-
sion between the inter- and intra-stromal samples was
analyzed by the Limma package available at the Biocon-
ductor website. P-values obtained from the multiple com-
parison tests were corrected by false discovery rates. The
microarray data has been deposited in the public reposi-
tory, Gene Expression Omnibus, accession number
GSE12306.
Immunohistochemistry
All reagents were obtained from Sigma (St. Louis, MO)
unless otherwise indicated. Ten-micron-thick sections of
frozen tissue were fixed in 1:1 methanol:acetone for 10
min and washed in 1× phosphate buffered saline, pH 7.4
(PBS). Endogenous peroxidase activity was blocked by a
10 min incubation in 3% hydrogen peroxide followed by
a 10 min wash in 1× PBS. Immunostaining was carried
out using the Vectastain ABC kit (Vector, Burlingame, CA)
according to the manufacturer's instruction. Color was
developed with diaminobenzidine peroxidase substrate
kit (Vector), and sections were counterstained with hema-
toxylin. Antibodies were obtained from the following
sources: Met, Cell Signaling Technologies (Boston, MA);
SOS2, Santa Cruz Biotechnology (Santa Cruz, CA);
Tenascin-C, Invitrogen (Gaithersburg, MD); CD44, BD
Biosciences (San Jose, CA); CD13, Novocastra (Visions
Biosystems Bannockburn IL); CD26, Abcam Inc. (Cam-
bridge, MA). Collagen staining with Sirius red was per-
formed as previously described [23]. A positive and
negative control was included in each experiment to vali-
date the specificity of each antibody. A breast tissue sam-
ple that had been previously determined to express high
levels of the protein of interest was used as a positive con-
trol. A serial section of each sample that received all stain-
ing steps, with the exception of the primary antibody, was
used as a negative control.
Reverse Transcription and PCR
Reverse transcription (RT) reactions were performed with
0.5 μg of total RNA isolated from LCM using Moloney
murine leukemia virus reverse transcriptase (Invitrogen)
primed with oligo-dT and random hexamers in a final vol-
ume of 25 μL. PCR was performed on 2.5 μL RT product
using PCR Master Mix (Roche, Indianapolis, IN) with
0.2–0.4  μM of each primer. Primer sequences can be
found in Table 1. Conditions for each PCR reaction were
as follows: 94°C for 3 min for one cycle, followed by
94°C for 1 min, 60°C for 1 min, 72°C for 2 min, with a
final extension at 72°C for 10 min. For a given experi-
ment, PCR was performed using a predetermined number
of cycles that spanned the linear range for the samples
tested (20–30 cycles). RT-PCR products were resolved by
agarose gel electrophoresis, visualized with ethidium bro-
mide, quantified using NIH Image, and normalized to the
respective level of GAPDH mRNA. Semi-quantitative RT-
PCR analyses were conducted on a minimum of three
patient samples. Appropriate negative controls were
included for each RT-PCR.
Results and discussion
Microarray analysis was employed to identify genes that
were differentially regulated between the intralobular and
interlobular stromal subtypes. Normal human mammary
tissue was obtained from healthy, pre-menopausal, reduc-
tion mammoplasty patients with no incidence of neopla-
sia. For each sample collected, tissue sections with
distinctive intralobular and interlobular regions were
selected for laser capture and microarray analysis (Fig. 1).
RNA was extracted from the samples, checked for quality,
and then hybridized with the Affymetrix Human
Genome133A GeneChips, containing over 22,000 oligo-
nucleotide probes. Surprisingly, no significant difference
in gene expression was found between the two stroma
subtypes. The microarray data demonstrated a wide range
of expression values and a 45-degree straight line in each
pair of samples, indicating the microarray assay and the
normalization procedure were valid. Despite the small
sample number, the scatter plots showed limited spread
of the off-diagonal lines, suggesting that any differential
Table 1: Primer sequences
Primer Primer sequences (listed 5' – 3')
GAPDH Forward CATGTGGGCCATGAGGTCCACCAC
Reverse TGAAGGTCGGTGTGAACGGATTTGGC
c-Met Forward ACCTGCTGAAATTGAACAGCGAGC
Reverse ACACTTCGGGCACTTACAAGCCTA
SOS2 Forward TAGAGAAAGGCGAGCAGCCAATCA
Reverse AGGGTGAGATTTGTGGTATGGCGA
CD44 Forward GCCTGGCGCAGATCGATTTGAATA
Reverse CCCTGTGTTGTTTGCTGCACAGAT
Tenascin-C Forward AGATGTCACAGACACCACTGCCTT
Reverse TGTGGCTTGTTGGCTCTTTGGAAC
CD13 Forward TCCACACCTTTGCCTACCAGAACA
Reverse TGCCTGATGTGCTGAAGAGATCGT
CD26 Forward TGGAGGCATTCCTACACAGCTTCA
Reverse ACAGCTCCTGCCTTTGGATATGGABMC Cell Biology 2008, 9:46 http://www.biomedcentral.com/1471-2121/9/46
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expression between samples is subtle, and not significant
(Fig. 2A). A heatmap with dendrograms was also gener-
ated from the data (Fig. 2B). At first glance, genes from
sample numbers 13L, 27L, and 29R appeared to separate
as different clusters with respect to interlobular and intral-
obular samples. However, further in-depth analysis using
hierarchical clustering of the samples, based on the 1,115
most variable genes, did not reveal a distinct expression
pattern between the intralobular and interlobular stromal
tissues, further indicating there was no significant differ-
ence in terms of gene expression at the transcriptional
level. Six of the genes with the largest difference in expres-
sion levels between intralobular in interlobular stroma are
listed in Table 2, along with the fold-change and p-value.
The lowest p-value was found to be 0.4726, which is far
from statistically significant. In order to validate the
microarray data, RT-PCR was performed on three of the
top six genes listed in Table 2. The RT-PCR products from
three patient samples as well as the quantitation of the
products are shown in Figure (3A&3B). The expression
levels of c-Met, SOS2, and CD44 reflect the findings of the
microarray data; there was no significant difference
between the intralobular and interlobular stroma.
Examples of protein levels reflecting the gene expression 
levels between intralobular and interlobular stroma
While the microarray and supportive RT-PCR analysis
revealed no significant difference between gene expres-
sion levels, previous reports have documented a distinc-
tive immunohistochemical difference between
intralobular and interlobular stroma [23-27]. Therefore,
we investigated whether we could observe a similar phe-
nomenon using the same patients tissue samples utilized
in the microarray analysis. We first investigated the pro-
tein expression of c-Met, the gene with the smallest p-
value (0.4726). Fixed preparations of human mammary
tissue from the four patients used in the microarray anal-
ysis, as well as additional samples, were immunoassayed
using a specific antibody for c-Met. As shown in Figure 3C,
all of the stroma uniformly stained positive for c-Met pro-
tein expression, with no detectable difference between the
two stroma subtypes. The c-Met gene encodes the tyrosine
kinase receptor for the hepatocyte growth factor/scatter
factor (HGF/SF). c-Met/HGF signaling is required for
mammalian embryogenesis and is important in cell
migration, morphogenic differentiation, cell growth and
angiogenesis. In normal breast tissue, c-Met was reported
to be associated with ductal cells, and involved in ductal
branching [28]. Additionally, the overexpression of c-Met
has been shown to contribute to the development and
progression of different human malignancies including
lung, prostate, colorectal, gastric, and breast cancer [29].
Recently, it was reported that c-Met protein is overex-
pressed in inflammatory breast cancer compared to non-
inflammatory breast cancer, and that an imbalance of c-
Met protein expression between tumor and surrounding
normal tissue is associated with an aggressive DCIS phe-
notype [30,31]. In the present study, c-Met protein was
easily detectable and uniformly distributed throughout
the normal breast.
We next investigated the protein expression pattern of
SOS2 (Son of Sevenless), the gene with the second lowest
p-value (0.7845). SOS2 is a Ras-specific nucleotide-
Identification of intralobular and interlobular stroma in normal human breast tissue Figure 1
Identification of intralobular and interlobular stroma in normal human breast tissue. Hemotoxylin and eosin stain-
ing of 8–10 micron sections of normal mammary tissue. The intralobular stroma isolated for laser capture microscopy is out-
lined in green while the interlobular stroma is outlined in black. Scale bar = 200 μM.BMC Cell Biology 2008, 9:46 http://www.biomedcentral.com/1471-2121/9/46
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exchange factor that is involved in the receptor tyrosine
kinase-Ras-ERK cascade [32]. This cascade has been impli-
cated in the control of diverse biological processes includ-
ing cell proliferation, differentiation, and survival. All
tissues immunoassayed for SOS2 showed sparse, weak,
staining in the stroma with no detectable difference in the
staining pattern between the stroma subtypes (Fig. 3C).
The only significant positive staining was found in the
luminal epithelium of each sample.
CD44, a protein which has recently gained much atten-
tion in breast cancer [33-37], is a ubiquitously expressed,
multifunctional cell surface adhesion molecule involved
in cell-cell and cell-matrix interactions, cell trafficking,
and transmission of numerous growth signals [38]. The
primary ligand for CD44 is hyaluronic acid, which is an
important component of the extracellular matrix. How-
ever, other CD44 ligands include collagen, fibronectin,
laminin, and chondroitin sulfate. Stromal hyaluronic acid
levels are a strong, independent, negative predictor for
patient survival in breast cancer [39,40]. Additionally,
many cancer cells overexpress CD44 or express CD44 var-
iants [41]. Mouse models of breast cancer tumorigenicity
have suggested that CD44 expression is a cell surface
marker that differentiates tumor initiating from non-tum-
origenic breast cancer cells in immuno-compromised
mice [42]. Furthermore, injection of reagents interfering
with CD44-ligand interaction, such as CD44-specific anti-
bodies, has been shown to inhibit local tumor growth and
metastatic spread in mouse models of human cancer [38].
These findings suggest that CD44 may confer a growth
advantage on some neoplastic cells and, therefore, could
be used as a target for cancer therapy. In the present study,
CD44 was one of the top genes with differential regula-
tion between intralobular and interlobular stroma,
although the p-value was 0.7845 and not significant.
Immunohistochemical analysis reflected the microarray
and RT-PCR results. There was uniform staining of the
stroma, and the highest immuno-reactivity for CD44 was
found in the epithelial cells (Fig. 3C).
Scattered plots of normalized data and unsupervised hierarchical clustering of the samples and genes Figure 2
Scattered plots of normalized data and unsupervised hierarchical clustering of the samples and genes. A. Raw 
intensity data was background-corrected and normalized as described in Materials and Methods. The normalized data from 
seven samples were plotted against one sample (SB13L-Intra). B. 1,115 most variable genes were used for hierarchical cluster-
ing among samples. The gene expression values were scaled by row and shown in the heat map.BMC Cell Biology 2008, 9:46 http://www.biomedcentral.com/1471-2121/9/46
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Examples of proteins differentially regulated between the 
intralobular and interlobular stroma, with no significant 
change in gene expression
As previously stated, several reports illustrate a difference
in protein expression between the intralobular and inter-
lobular stroma. Atherton et al. (1998) reported that
immuno-localization of type XIV collagen/undulin in the
human mammary gland revealed greater deposition in
the interlobular stroma than in the intralobular stroma
[25]. Fibroblasts isolated from the interlobular stroma
synthesized 3- to 5-fold more type XIV collagen/undulin
than intralobular fibroblasts, but synthesized type I and
type IV collagens in similar amounts. The authors suggest
this protein is a way to separate the two types of distinct
stroma for analysis. Collagen fibers have also been
reported to be more abundant and densely packed
c-Met, SOS2, and CD44 expression levels in intralobular and interlobular normal human breast stroma Figure 3
c-Met, SOS2, and CD44 expression levels in intralobular and interlobular normal human breast stroma. A. RT-
PCR analysis of the indicated genes expression. B. Mean ± SD gained by densitometric examination of RT-PCR product from 
three independent samples. C. Tissues were subjected to immunohistochemical analysis with the specific antibody indicated 
(left panels) or corresponding negative controls (right panels). Scale bar = 200 μM.
Table 2: Top six genes with the highest p-value
Gene name Accession number Log fold change P-value
C-Met AA005141 -0.4891 0.4726
SOS2 AI276593 -0.4345 0.7845
CPT1A BC000185 -0.4465 0.7845
PDLIM7 AW206786 -0.3722 0.7845
TSC22D2 AF201292 -0.4455 0.7845
CD44 AW851559 -0.4704 0.7845BMC Cell Biology 2008, 9:46 http://www.biomedcentral.com/1471-2121/9/46
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throughout interlobular stroma compared to intralobular
stroma in the bovine mammary gland [23]. Thus, we
examined the collagen fiber deposition in the tissue sam-
ples from the patients used in the microarray data. Using
Sirius Red, a pan stain for collagen fibers, there was a clear
visible difference in the deposition of collagen fibers
between the two types of stroma (Fig. 4A). In our micro-
array data, the fold change and p-value for type XIV colla-
gen/undulin were -0.199 and 0.785, respectively. Undulin
had the best p-value compared to all other types of colla-
gen, but again, no values for any of the collagen genes
were significant. RT-PCR analysis of the patients samples
used in the microarray revealed an inconsistent expression
of undulin between samples, resulting in no significant
change between intralobular and interlobular expression
(Fig. 4B&4C).
Our current data illustrated that the interlobular stroma
has increased stromal collagen compared to the intralob-
ular stromal. Mammographically dense breast tissue is
one of the greatest risk factors for developing breast carci-
noma, and regions of high breast density are associated
with increased stromal collagen [43-45]. A recent report
investigating the effects of collagen density on mammary
tumor formation and progression utilized a bi-transgenic
tumor model with increased stromal collagen in mouse
mammary tissue [46]. This increased stromal collagen sig-
nificantly increased tumor formation and resulted in a sig-
Localization and expression levels of collagen fibrils, CD13, Tenascin-C, and CD26 in intralobular and interlobular normal  human breast stroma Figure 4
Localization and expression levels of collagen fibrils, CD13, Tenascin-C, and CD26 in intralobular and interlob-
ular normal human breast stroma. A. Tissues were stained with Sirius Red alone (top panel) or with Fast Green counter-
stain (bottom panel). B. RT-PCR analysis of the indicated genes expression. C. Mean ± SD gained by densitometric examination 
of RT-PCR product from three independent samples. D. Tissues were subjected to immunohistochemical analysis with the spe-
cific antibody indicated (left panels) or corresponding negative controls (right panels). Note large quantities of intensely stained 
interlobular stroma (asterisks) compared to the paler-staining intralobular stroma (arrow). Scale bar = 200 μM.BMC Cell Biology 2008, 9:46 http://www.biomedcentral.com/1471-2121/9/46
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nificantly more invasive phenotype, with increased lung
metastasis. This study provided the first data causally link-
ing increased stromal collagen to mammary tumor forma-
tion and metastasis, and demonstrated that fundamental
differences arise and persist in epithelial tumor cells that
progressed within collagen-dense microenvironments. It
could be hypothesized that a change in the protein expres-
sion of the intralobular stroma to mimic the collagen
expression of the interlobular stroma would enhance
breast cancer progression. Studying the mechanisms,
which lead to the differential levels in collagen deposition
between these two stromal subtypes, could facilitate in
understanding the physiology of breast density and the
resultant influences on mammary epithelial cell function.
Tenascin-C has also been reported to be expressed in the
intralobular stroma as well as in the basement and sub-
basement membrane zone of normal breast tissue [47].
Tenascin-C is a member of the tenascin family of modular
and multifunctional extracellular matrix glycoproteins.
These molecules are expressed in the adult during normal
processes such as wound healing and tissue involution,
and in pathological states including vascular disease, tum-
origenesis, and metastasis [48]. In the present study, there
was substantially more immuno-staining in the intralob-
ular stroma compared to the interlobular stroma (Fig.
4D). Both the sub-basement membrane as well as the
stroma had higher immuno-reactivity compared to the
interlobular stroma. The microarray data reported a -
0.119 fold change and a p-value of 0.852 for tenascin-C.
RT-PCR was also performed on the same patient samples,
and similar to the microarray data, showed no significant
difference in tenascin-C expression (Fig. 4B&4C).
Tenascin-C has been reported to be overexpressed in the
extracellular matrix of the stroma in many solid tumors,
including breast tumors [49,50]. Additionally, expression
of tenascin-C in DCIS has been demonstrated to predict
invasion, and high expression has been related to poor
prognosis, as well as local and distant reoccurrence in
breast cancer patients. [51-55]. Interestingly, both the dis-
tribution and quantity of tenascin-C changes in the breast
during the menstrual cycle [47], which may explain the
variations in tenascin staining in normal tissue, as well as
hormone-dependent and independent tumors. Although
intralobular stroma was reported to undergo cyclic
changes during the menstrual cycle [56], there was no
measurable difference in protein levels of the estrogen
and progesterone receptor status within the two types of
stroma (data not shown). Similar to the results seen with
the collagen deposition, this is another example of gene
expression levels that do not reflect the abundance of the
protein between the two types of stroma.
Atherton et al. (1994) have reported a unique regulation
of ectoenzymes between the intralobular and interlobular
stroma [26]. In normal breast tissue, aminopeptidase N
(CD13) was reported to be uniformly expressed in all
stroma, while dipeptidyl peptidase IV (CD26) was absent
in the intralobular stroma, but present in the interlobular
stroma. The two subpopulations of stromal cells were iso-
lated by enzymatic digestion and cell culture, and then
analyzed via flow cytometry and immunohistochemistry.
Interestingly, after several passages on tissue plastic cul-
ture dishes, the intralobular stroma lost their expression
of CD26 and became phenotypically similar to the inter-
lobular fibroblasts. This suggests that growth on tissue
culture plastic causes a reversion of the stroma subpopu-
lations to one phenotype. We subjected the patient sam-
ples from the microarray data to both
immunohistochemistry and RT-PCR for both CD13 and
CD26. In contrast to Atherton's report, immunohisto-
chemical analysis of CD13 illustrated a predominately
intralobular stroma staining in all patient samples tested
(Fig. 4D). However, similar to the microarray data, RT-
PCR analysis showed inconsistent expression levels
between patients (Fig 4B&4C). Of the four patients used
in the microarray analysis, two samples had higher CD13
expression in the intralobular stroma, while the other two
had higher expression in the interlobular stroma. A larger
sample size is necessary to determine whether the RT-PCR
results were significant. Additionally, the intensity of the
immunoreactivity may be attributed to the density of the
stromal cells between the stroma subtypes, and the overall
stromal density of each patient may influence the immu-
nohistochemical analysis and a larger sample size is
required for absolute conclusion.
As with CD13, CD26 demonstrated inconsistent staining
between samples, without specific staining to the intral-
obular or interlobular stroma (Fig. 4D). In some patient
samples, CD26 demonstrated a slightly greater deposition
in interlobular stroma than intralobular stroma, while in
other samples CD26 was ubiquitously expressed through-
out all stroma. The RT-PCR results reflected the inconsist-
ency of CD26 protein expression, and similar to the
microarray data, quantitation of the samples resulted in
no significant difference in expression (Fig. 4B&4C).
Conclusion
Recently it was reported that the gene expression signa-
tures of cancer-adjacent and breast reduction-normal tis-
sues were essentially homogeneous and not
distinguishable [57]. The stroma used in this microarray
study was exclusively interlobular stroma, and specifically
excluded any intralobular stroma. The authors state this
was the most complete study to date of gene expression in
normal breast tissue, and that normal tissue adjacent to
breast carcinomas has not undergone significant gene
expression changes. However, the present study highlights
the importance of post-transcriptional or post-transla-BMC Cell Biology 2008, 9:46 http://www.biomedcentral.com/1471-2121/9/46
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tional regulation of proteins. Since surgery is a common
procedure performed on tissue with potential for tumor
progression, the alterations in the adjacent stroma could
have important clinical implications. This study empha-
sizes the importance of using techniques other than gene
expression levels to investigate protein regulation within
the stroma.
A recent report utilizing two-dimensional gel electro-
phoresis supports the present study and shows that carci-
noma-associated fibroblasts, tumor-adjacent fibroblasts
(cells 2 cm away from the tumor margin), and normal
breast fibroblasts have different proteome profiles, with
many different proteins differentially expressed among
these cells [58]. Interestingly, the carcinoma-associated
fibroblasts and tumor-adjacent fibroblasts expressed high
levels of the cancer marker survivin and consequently
exhibited high resistance to the chemotherapeutic agent
cisplatin and UV light. Furthermore, the tumor-adjacent
fibroblasts, although histologically normal and not in
contact with the tumor cells, contained genetic changes
that were distinct from the normal fibroblasts and the car-
cinoma-associated fibroblasts. It was hypothesized that
the carcinoma-associated fibroblasts, as well as their cor-
responding tumor-adjacent fibroblasts, acquired tumor-
like changes that are necessary for tumor growth. The
authors further speculated that certain genes are up-regu-
lated early during carcinogenesis and have a promoting
role during cancer development. It would be of interest to
investigate, based on the data obtained from the present
study, whether the carcinoma-associated fibroblasts and
tumor-adjacent fibroblasts arise from the intralobular or
the interlobular stroma, and what effects tumorigenic
changes in either subtype have on each other and the pro-
gression of the cancer.
The failure to grow normal or premalignant human mam-
mary epithelial cells in vivo had previously hindered any
possibility of a model for human breast cancer progres-
sion using human cells. Recently, Kuperwasser et al. [12]
successfully developed a dynamic in vivo model which
recapitulates human breast epithelial morphogenesis. In
this model, human mammary fibroblasts are injected into
the gland and allowed to grown into the gland and
"humanize" the mouse fat pad, prior to injection of the
epithelial cells. This model demonstrated that stroma pro-
moted the normal or premalignant to malignant growth
of the epithelial cells, depending on the type of fibroblasts
used. It may be informative to observe the differences in
the normal outgrowth or tumorigenesis of epithelial cells
when either intralobular or interlobular fibroblasts are
chosen to humanize the gland. Furthermore, future stud-
ies isolating the differences between these two stromal
subtypes may bring further insight into the tumor/stroma
environment as well as normal mammary development.
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